Holen Sie sich die Stockscreener-App
3.18
3.34%
-0.11
Vorhandelsmarkt:
3.18
Schlusskurs vom Vortag:
$3.29
Offen:
$3.27
24-Stunden-Volumen:
15.41M
Relative Volume:
1.01
Marktkapitalisierung:
$1.69B
Einnahmen:
$66.41M
Nettoeinkommen (Verlust:
$-559.78M
KGV:
-2.6452
EPS:
-1.2022
Netto-Cashflow:
$-328.09M
1W Leistung:
-1.24%
1M Leistung:
+8.53%
6M Leistung:
-24.29%
1J Leistung:
-36.40%
1-Tages-Spanne:
$3.16
$3.34
1-Wochen-Bereich:
$2.95
$3.39
52-Wochen-Spanne:
$2.77
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Firmenname
Recursion Pharmaceuticals Inc
Sektor
Branche
Telefon
(385) 269-0203
Adresse
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.18 | 1.75B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Eingeleitet | Needham | Buy |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-04 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Eingeleitet | Berenberg | Buy |
| 2021-05-11 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Eingeleitet | JP Morgan | Neutral |
| 2021-05-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
Recursion Pharmaceuticals (RXRX) Stock Valuation After AI Drug Discovery And REC-1245 REC-4881 Updates - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Recursion Pharmaceuticals: Short-Trade Crowded But Near-Term Squeeze Not Guaranteed (RXRX) - Seeking Alpha
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI-Driven Drug Discovery Advances - Quiver Quantitative
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
RXRX: AI-driven platform advances multiple clinical programs with major data readouts expected soon - TradingView
Recursion Pharmaceuticals (RXRX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Here’s Why Recursion Pharmaceuticals (RXRX) is Among the Best Penny Stocks - Insider Monkey
Recursion Pharmaceuticals Stock Surges After Consecutive Losses - asatunews.co.id
Insider Sell: Najat Khan Sells Shares of Recursion Pharmaceutica - GuruFocus
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Gibson Christopher - Moomoo
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Khan Najat - Moomoo
Insider Sell: Najat Khan Sells Shares of Recursion Pharmaceuticals Inc (RXRX) - GuruFocus
Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock - Investing.com UK
Recursion Pharmaceuticals Inc (RXRX) Stock Price, Quote, News & History - Benzinga
Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock By Investing.com - Investing.com Australia
Recursion Pharma director Christopher Gibson sells $144,800 in stock By Investing.com - Investing.com Australia
Recursion Pharma director Christopher Gibson sells $144,800 in stock - Investing.com
Recursion (NASDAQ: RXRX) director sells 40,000 shares under 10b5-1 plan - Stock Titan
Recursion Pharmaceuticals (RXRX) CEO sells 23,588 shares in planned Rule 10b5-1 trade - Stock Titan
Recursion Q1 2026 slides: pipeline advances amid revenue shortfall - Investing.com
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Najat Khan plans Rule 144 sale of Recursion (NASDAQ: RXRX) shares on 05/15/2026 - Stock Titan
Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After Positive AI Drug Data And Extended Cash Runway - Sahm
Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Gibson files Form 144 to sell 40,000 Class A shares (RXRX) - Stock Titan
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Bumpus Namandje - Moomoo
Recursion (RXRX) Climbs 9.5% Ahead of Next Week’s Business Updates - Insider Monkey
9 Stocks Crushing the Market With Surging Returns - Insider Monkey
Insider Sell: Namandje Bumpus Sells Shares of Recursion Pharmace - GuruFocus
10 Best Penny Stocks with Huge Upside Potential - Insider Monkey
Recursion (RXRX) director Bumpus sells 4,386 shares under Rule 10b5-1 plan - Stock Titan
Recursion (NASDAQ: RXRX) director sells 30,000 shares under 10b5-1 plan - Stock Titan
RXRX Stock Grinds Higher As Earnings Beat Supports AI Drug Story - timothysykes.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on Clinical Proof and AI Platform Advancements - Quiver Quantitative
RXRX Stock Climbs As Earnings Beat Highlights AI Drug Progress - StocksToTrade
Recursion Stock Jumps Before Goldman Sachs Event as AI-Drug Trade Gets Fresh Heat - TechStock²
RXRX Stock Climbs As Earnings Beat Extends Cash Runway - timothysykes.com
Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After AI Pipeline Progress And Stronger-Than-Expected Q1 Results - Yahoo Finance
Earnings call transcript: Recursion Pharmaceuticals Q1 2026 results show EPS beat but revenue miss - Investing.com
Recursion’s AI Drug Pipeline Progress Tests Investor Patience And Valuation - Yahoo Finance
[144] RECURSION PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? - AOL.com
JP Morgan Upgrades Recursion Pharmaceuticals (RXRX) - MSN
Earnings call transcript: Recursion Pharmaceuticals beats EPS, revenue miss Q1 2026 - Investing.com Nigeria
Recursion vs. Schrodinger: Comparing Biotech and Software Drug Discovery Strategies in 2026News and Statistics - IndexBox
Recursion Pharmaceuticals to present at Goldman Sachs Healthcare Conference on June 9, 2026 - Pluang
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
A Look At Recursion Pharmaceuticals (RXRX) Valuation As Shares Show Short Term Momentum - simplywall.st
RXRX (NASDAQ) affiliate sales reported: Borgeson sells 230,000 shares in 2026 - Stock Titan
Finanzdaten der Recursion Pharmaceuticals Inc-Aktie (RXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Recursion Pharmaceuticals Inc-Aktie (RXRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Khan Najat | CEO and President |
Jun 05 '26 |
Sale |
3.58 |
23,588 |
84,459 |
2,175,796 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):